Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Get Free Report) gapped down before the market opened on Tuesday . The stock had previously closed at $15.40, but opened at $14.56. Telix Pharmaceuticals Limited American Depositary Shares shares last traded at $14.80, with a volume of 469 shares changing hands.
Wall Street Analyst Weigh In
Several analysts recently weighed in on TLX shares. UBS Group began coverage on Telix Pharmaceuticals Limited American Depositary Shares in a report on Friday, November 15th. They set a "buy" rating and a $21.00 price target on the stock. William Blair upgraded shares of Telix Pharmaceuticals Limited American Depositary Shares to a "strong-buy" rating in a report on Tuesday, November 19th.
Get Our Latest Analysis on TLX
Telix Pharmaceuticals Limited American Depositary Shares Trading Up 3.1 %
About Telix Pharmaceuticals Limited American Depositary Shares
(
Get Free Report)
Telix Pharmaceuticals Limited is a biopharmaceutical company which focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It involved in developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases.
Further Reading
Before you consider Telix Pharmaceuticals Limited American Depositary Shares, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals Limited American Depositary Shares wasn't on the list.
While Telix Pharmaceuticals Limited American Depositary Shares currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
